May Hill Capital LLC Acquires New Position in Haemonetics Co. (NYSE:HAE)

May Hill Capital LLC acquired a new position in shares of Haemonetics Co. (NYSE:HAE - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 17,915 shares of the medical instruments supplier's stock, valued at approximately $1,399,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. BNP Paribas Financial Markets raised its stake in Haemonetics by 174.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 16,949 shares of the medical instruments supplier's stock worth $1,362,000 after acquiring an additional 10,774 shares during the last quarter. Boston Trust Walden Corp raised its stake in shares of Haemonetics by 13.1% in the fourth quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier's stock worth $71,500,000 after purchasing an additional 106,114 shares during the last quarter. FMR LLC lifted its holdings in shares of Haemonetics by 206.3% during the third quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier's stock worth $62,257,000 after purchasing an additional 521,640 shares during the period. Empowered Funds LLC purchased a new stake in Haemonetics in the fourth quarter valued at approximately $319,000. Finally, Pacer Advisors Inc. increased its holdings in Haemonetics by 36.1% in the 4th quarter. Pacer Advisors Inc. now owns 10,104 shares of the medical instruments supplier's stock worth $789,000 after buying an additional 2,680 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Haemonetics Price Performance

HAE traded down $1.42 during trading on Friday, hitting $60.80. The company's stock had a trading volume of 1,019,545 shares, compared to its average volume of 671,984. The firm has a market capitalization of $3.05 billion, a price-to-earnings ratio of 23.94, a P/E/G ratio of 1.11 and a beta of 0.43. Haemonetics Co. has a twelve month low of $58.80 and a twelve month high of $97.97. The business's fifty day simple moving average is $65.01 and its 200 day simple moving average is $74.25. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. On average, equities research analysts forecast that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Bank of America cut shares of Haemonetics from a "neutral" rating to an "underperform" rating and decreased their price objective for the company from $95.00 to $68.00 in a research note on Friday, February 7th. JMP Securities lowered their price target on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a report on Friday, February 7th. Barrington Research cut their price target on Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. JPMorgan Chase & Co. began coverage on Haemonetics in a report on Friday, December 6th. They issued an "overweight" rating and a $116.00 price objective for the company. Finally, StockNews.com lowered Haemonetics from a "buy" rating to a "hold" rating in a report on Saturday, February 15th. One analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $101.22.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.